DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
Rhea-AI Summary
LIXTE Biotechnology (Nasdaq: LIXT) is the sponsor of the inaugural Good Health: Mind, Body & Soul Summit led by De La Soul on February 19, 2026 at Morehouse College in Atlanta. The invitation-only event convenes health experts, artists, athletes, researchers, and advocates to advance health equity for Black men and families. Programming covers cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness, linking science and lived experience. Attendance is by invitation; more information is available at the summit website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LIXT gained 3.95%, reflecting a moderate positive market reaction. Argus tracked a peak move of +20.3% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $756K to the company's valuation, bringing the market cap to $20M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LIXT fell 8.43% while key peer AKTX appeared in momentum scanners moving up (+8.75%). Other peers showed mixed to flat moves, suggesting today’s action was stock-specific rather than a sector-wide biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Trial expansion | Positive | -1.9% | Expanded clear cell ovarian cancer trial enrollment from 21 to 42 patients. |
| Dec 18 | Equity offering | Negative | -1.0% | $4.3M registered direct offering at-the-market under Nasdaq rules. |
| Dec 08 | Strategy update | Positive | +7.2% | Acquisition of Liora and LiGHT radiotherapy platform to build oncology platform. |
| Dec 03 | Platform shift | Positive | +3.5% | Advanced LB-100 and added proton therapy assets plus digital-asset balance sheet moves. |
| Dec 03 | Clinical progress | Positive | +3.5% | Positioned LB-100 as amplifier with funded GSK and Roche collaborations. |
Recent news has generally seen price gains on strategic and clinical updates, with a tendency to sell off on financing or even some positive trial news.
Over the past two months, LIXT has reported several strategic and clinical milestones. On Dec 3, 2025, it highlighted LB-100 as a treatment amplifier and described a shift toward a multi-modal oncology platform, with positive price reactions around +3.45%. The acquisition of Liora and radiotherapy assets on Dec 3 and strategy update on Dec 8 both aligned with gains. A $4.3M registered direct offering on Dec 18 and an ovarian cancer trial expansion on Dec 23 saw modest declines, indicating sensitivity to dilution and some positive news being sold.
Market Pulse Summary
This announcement highlights LIXT’s sponsorship of a February 19 health equity summit, linking its LB-100 oncology program and LIORA subsidiary to community-focused cancer and wellness discussions. It follows recent strategic moves toward a multi-modal oncology platform and an expanded ovarian cancer trial expected to yield data in 1H 2026. Investors may watch how such outreach supports trial enrollment, brand positioning, and follow-on clinical or regulatory milestones.
Key Terms
oncology medical
AI-generated analysis. Not financial advice.
Event Sponsored by LIXTE Biotechnology Holdings,
Developer of Breakthrough Cancer Therapies
Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & Soul Summit will take place February 19 at Morehouse College in Atlanta.
This invitation-only event brings together leaders in health, culture, science, and community to advance health equity for Black men and families. It is made possible by the generous sponsorship of LIXTE Biotechnology Holdings Inc (Nasdaq: LIXT), a clinical-stage pharmaceutical company developing breakthrough cancer therapies.
Rooted in the group’s song “Good Health,” written after the passing of founding member David Jolicoeur (Trugoy the Dove), the Summit represents the next chapter in De La Soul’s commitment to truth, wellness, and cultural impact. Developed in collaboration with Blacksmith holdings, the Summit reflects the group’s evolution from musical pioneers to wellness advocates. Together, De La Soul and Blacksmith partnered with leaders in healthcare, culture, and research to bring the Summit to life.
“This Summit is about turning pain into purpose,” said Kelvin Mercer (Posdnuos). “We’ve always used our music to speak life—and Good Health is about making sure our people live long enough to tell their own stories.”
“This isn’t just a conversation—it’s a call,” added Vincent Mason (Maseo). “Good health is real wealth. We’re creating space for Black men, families, and communities to own that truth—together.”
“Good Health aligns science with culture in a way that is both urgent and deeply human,” said Geordan Pursglove, CEO of LIXTE Biotechnology. “Through our first-in-class oncology compound, LB-100, and LIORA, our European research subsidiary, we are committed to advancing cancer care. This Summit is a powerful space to connect that innovation to the communities that need it most.”
The Summit will convene an intimate audience of health experts, artists, entertainers, athletes, researchers, and advocates. Programming will span topics across mind, body, and soul—including cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness—grounded in science and lived experience.
Attendance is by invitation only. For more details, visit www.goodhealthsummit.com.
About De La Soul
De La Soul is the New York–based trio composed of Posdnuos, Trugoy, and Maseo, creators of the groundbreaking 1989 album 3 Feet High and Rising. Known for their inventive sampling, creative lyricism, and foundational influence on jazz rap and alternative hip-hop, the group has earned widespread acclaim, including a Grammy Award for “Feel Good Inc.” with Gorillaz. Their 2015 Kickstarter-funded album and the Anonymous Nobody… topped the Rap Albums chart and earned a Grammy nomination for Best Rap Album.
For more information and updates on De La Soul, visit:
Website
Facebook
Twitter
BlueSky
Instagram
TikTok
About Blacksmith Holdings
Blacksmith Holdings is a 360° entertainment company founded by Corey Smyth, focused on building culturally driven platforms that connect art, community, and purpose. With a legacy that includes guiding the careers of Dave Chappelle, Vince Staples, Mos Def, and Talib Kweli. Blacksmith continues to champion initiatives that advance wellness, equity, and long-term impact. Additional information about Blacksmith can be found at www.blacksmithnyc.com
About LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
What is the Good Health Summit sponsored by LIXT and when is it?
Who is leading the Good Health Summit and what is its focus?
Will LIXT discuss its oncology work at the February 19 summit (LIXT)?
Who can attend the Good Health Summit at Morehouse College?
Where can investors or attendees find more details about the LIXT-sponsored summit?
